Wearable cardioverter defibrillator: bridging for implantable defibrillators in left ventricular assist device...

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Implantable cardioverter-defibrillators (ICDs) are beneficial for heart failure patients, but their efficacy in left ventricular assist device (LVAD) recipients is unclear.
• Lack of randomized controlled trial data leads to conflicting guidelines on routine ICD implantation in LVAD patients.
• Alternative strategies like subcutaneous ICDs (S-ICDs) have limited eligibility for LVAD patients.

Purpose of the Study:

• To review the current evidence and guidelines regarding ICD use in LVAD patients.
• To explore the potential role of wearable cardioverter defibrillators (WCDs) in managing arrhythmia risk in LVAD recipients.
• To address the clinical dilemma of de novo ICD implantation in LVAD candidates.

Main Methods:

• Review of existing literature and societal guidelines on ICD and LVAD therapy.
• Analysis of data regarding the effectiveness and limitations of different defibrillator strategies in LVAD patients.
• Discussion of the emerging role of wearable cardioverter defibrillators as a bridge to decision.

Main Results:

• Current data on ICD benefit in LVAD patients is conflicting, with no clear consensus in major guidelines.
• Subcutaneous ICD eligibility is often insufficient for the LVAD population.
• Wearable cardioverter defibrillators present a potential temporary solution for risk assessment and decision-making.

Conclusions:

• The optimal defibrillator strategy for LVAD patients remains an area of active investigation.
• Wearable cardioverter defibrillators may serve as a valuable tool to guide decisions on permanent defibrillator implantation in LVAD recipients.
• Further research, including randomized controlled trials, is needed to clarify the role of ICDs in LVAD therapy.